This website is intended exclusively for healthcare professionals. By clicking Yes, you confirm that you are a registered healthcare professional and understand that the content is not designed for the general public. If you are not a healthcare professional, you must click No and you will be redirected away. Misrepresentation of your status may result in legal consequences.
Skip to main content
ALECENSA® (alectinib) Great Britain
ALECENSA® (alectinib) Northern Ireland
Avastin® (bevacizumab) Great Britain
Avastin® (bevacizumab) Northern Ireland
Evrysdi®▼ (risdiplam) Great Britain
Evrysdi®▼ (risdiplam) Northern Ireland
GAVRETO® ▼ (pralsetinib) Great Britain
GAVRETO® ▼ (pralsetinib) Northern Ireland
GAZYVARO® (obinutuzumab) Great Britain
GAZYVARO® (obinutuzumab) Northern Ireland
HEMLIBRA® (emicizumab) Great Britain
HEMLIBRA® (emicizumab) Northern Ireland
Herceptin® (trastuzumab) IV Great Britian
Herceptin® (trastuzumab) IV Northern Ireland
Herceptin® (trastuzumab) SC Great Britain
Herceptin® (trastuzumab) SC Northern Ireland
Kadcyla®(trastuzumab emtansine) Great Britain
Kadcyla®(trastuzumab emtansine) Northern Ireland
Lunsumio®▼ (mosunetuzumab) Great Britain
Lunsumio®▼ (mosunetuzumab) Northern Ireland
OCREVUS® (ocrelizumab) Great Britain
OCREVUS® (ocrelizumab) Northern Ireland
Perjeta® (pertuzumab) Great Britain
Perjeta® (pertuzumab) Northern Ireland
PHESGO®▼ (pertuzumab/trastuzumab) Great Britain
PHESGO®▼ (pertuzumab/trastuzumab) Northern Ireland
Polivy®▼ (polatuzumab vedotin) Great Britain
Polivy®▼ (polatuzumab vedotin) Northern Ireland
Rozlytrek®▼ (entrectinib) Great Britain
Rozlytrek®▼ (entrectinib) Northern Ireland
TECENTRIQ® (atezolizumab) Great Britain
TECENTRIQ® (atezolizumab) Northern Ireland
Vabysmo®▼ (faricimab) Great Britain
Vabysmo®▼ (faricimab) Northern Ireland
Gavreto and Rozlytrek are subject to a conditional marketing authorisation.
Medicinal products that display the black triangle symbol ▼ are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 36 7554. For medicines which are biological, healthcare professionals should report adverse reactions by brand name and batch number.
You will be re-directed to an external website. Roche accepts no responsibility for the content of other websites.